Skip to main content

Advertisement

SpringerLink
Log in

Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support

  • ORIGINAL ARTICLE
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Introduction/objectives

Acute kidney injury (AKI) with the requirement of kidney replacement therapy (KRT) portends a poor prognosis for kidney function in lupus nephritis (LN). This study evaluated the kidney function recovery rates, the rates of reinitiation of KRT, and factors associated with these outcomes in LN.

Method

All consecutive patients hospitalized for LN with KRT requirement between 2000 and 2020 were included. Their clinical and histopathologic characteristics were retrospectively registered. The outcomes and associated factors were evaluated by multivariable Cox regression analysis.

Results

Among 140 patients, 75 (54%) recovered kidney function, with recovery rates of 50.9% and 54.2% by 6 and 12 months of therapy. The factors associated with a lower probability of recovery included a previous history of LN flares, worse eGFR and higher proteinuria at presentation, immunosuppression with azathioprine, and hospitalizations within 6 months of therapy initiation. There was no difference in the kidney function recovery rates between mycophenolate and cyclophosphamide treatment schemes. Out of 75 patients who recovered kidney function, 37 (49%) reinitiated KRT, with KRT reinitiation rates of 27.2% and 46.5% by 3 and 5 years. Seventy-three (52%) patients had at least one hospitalization within 6 months of initial therapy, 52 (72%) of them secondary to infectious events.

Conclusions

Approximately 50% of patients with LN and KRT requirement recover kidney function within 6 months. The risk-to-benefit ratio decisions may be aided by clinical and histological factors. These patients require close follow-up as ≈50% of those who recover kidney function will reinitiate dialysis in the long term.

Key Points

• Approximately 50% of patients with severe acute lupus nephritis with the need for kidney replacement therapy requirement recover their kidney function.

• The factors associated with a lower probability of recovery of kidney function include a previous history of LN flares, worse eGFR and higher proteinuria at presentation, immunosuppression with azathioprine, and hospitalizations within 6 months of therapy initiation.

• Patients who recover kidney function will require close follow-up as around 50% of them will eventually reinitiate kidney replacement therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data supporting this study is available upon reasonable request to the corresponding author.

References

  1. Mejia-Vilet JM, Rovin BH (2019) Chapter 59. Epidemiology and management of lupus nephritis. In: Wallace D, Hahn B (eds) Dubois Systemic Lupus Erythematosus and Related Syndromes, 9th edn. Elsevier, Philadelphia, PA, pp 727–744

    Chapter  Google Scholar 

  2. Zhu D, Qu Z, Tan Y, Yu F, Zhao M (2011) Acute kidney injury in Chinese patients with lupus nephritis: a large cohort study from a single center. Lupus 20(14):1557–1565. https://doi.org/10.1177/0961203311417035

    Article  CAS  PubMed  Google Scholar 

  3. Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L et al (2018) Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77(9):1318–1325. https://doi.org/10.1136/annrheumdis-2017-212732

    Article  CAS  PubMed  Google Scholar 

  4. Chen T, Ding X, Chen B (2009) Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis. Nephrol Dial Transplant 24(10):3115–3120. https://doi.org/10.1093/ndt/gfp235

    Article  PubMed  Google Scholar 

  5. Yu F, Tan Y, Liu G, Wang S, Zou W, Zhao M (2009) Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 76(3):307–317. https://doi.org/10.1038/ki.2009.136

    Article  PubMed  Google Scholar 

  6. Teh CL, Phui VE, Ling GR, Ngu LS, Wan SA, Tan CHH (2018) Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience. Clin Kidney J 11(1):56–61. https://doi.org/10.1093/ckj/sfx063

    Article  PubMed  Google Scholar 

  7. Furie R, Rovin BH, Houssiau F, Malvar A, Teng OYK, Contreras G et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117–1128. https://doi.org/10.1056/NEJMoa2001180

    Article  CAS  PubMed  Google Scholar 

  8. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397(10289):2070–2080. https://doi.org/10.1016/s0140-6736(21)00578-x

    Article  CAS  PubMed  Google Scholar 

  9. Walsh M, Solomons N, Lisk L, Jayne DRW (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 61(5):710–715. https://doi.org/10.1053/j.ajkd.2012.11.042

  10. Sun F, Wang H, Zhang D, Han F, Ye S (2022) One-year renal outcome in lupus nephritis patients with acute kidney injury: a nomogram model. Rheumatology 61(7):2886–2893. https://doi.org/10.1093/rheumatology/keab818

    Article  PubMed  Google Scholar 

  11. Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD et al (2023) Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol 38(5):1653–1665. https://doi.org/10.1007/s00467-022-05775-z

    Article  PubMed  Google Scholar 

  12. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I et al (2020) 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):S713–S723. https://doi.org/10.1136/annrheumdis-2020-216924

    Article  CAS  Google Scholar 

  13. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1–S276. https://doi.org/10.1016/j.kint.2021.05.021

    Article  Google Scholar 

  14. Singh JA, Hossain A, Kotb A, Wells G (2016) Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med 14(1):137. https://doi.org/10.1186/s12916-016-0673-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151–1159. https://doi.org/10.1136/annrheumdis-2018-214819

    Article  PubMed  Google Scholar 

  16. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521–530. https://doi.org/10.1111/j.1523-1755.2004.00443.x

    Article  PubMed  Google Scholar 

  17. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT et al (2018) Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93(4):789–796. https://doi.org/10.1016/j.kint.2017.11.023

    Article  PubMed  Google Scholar 

  18. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med 385(19):1737–1749. https://doi.org/10.1056/NEJMoa2102953

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jin SY, Huang DL, Dang XQ, Yi ZW (2017) Lupus glomerulonephritis in 788 Chinese children: a multi-centre clinical and histopathological analysis based on 549 renal biopsies. Paediatr Int Child Health 37(4):286–291. https://doi.org/10.1080/20469047.2017.1309337

    Article  PubMed  Google Scholar 

  20. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, Silverman ED (2009) Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 48(2):176–182. https://doi.org/10.1093/rheumatology/ken445

    Article  CAS  PubMed  Google Scholar 

  21. Ishimori S, Kaito H, Shima Y, Kamioka I, Hamahira K, Nozu K et al (2019) Clinicopathological characteristics and renal outcomes of childhood-onset lupus nephritis with acute kidney injury: a multicenter study. Mod Rheumatol 29(6):970–976. https://doi.org/10.1080/14397595.2018.1532861

    Article  PubMed  Google Scholar 

  22. Chen T, Zhou Y, Zhang J, Chen C, Pan J (2020) Long-term predictive value of acute kidney injury classification in diffuse proliferative lupus nephritis with acute kidney injury. BMC Nephrol 21(1):13. https://doi.org/10.1186/s12882-019-1676-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM (2013) Recovery of renal function among ESRD patients in the US Medicare program. PLoS One 8(12):e83447. https://doi.org/10.1371/journal.pone.0083447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sekkarie MA, Port FK, Wolfe RA, Guire K, Humphrys R, Amburg GV, Ferguson CW (1990) Recovery from end-stage renal disease. Am J Kidney Dis 15(1):61–65. https://doi.org/10.1016/S0272-6386(12)80593-2

    Article  CAS  PubMed  Google Scholar 

  25. Ku E, Hsu RK, Johansen KL, McCulloch CE, Mitsnefes M, Grimes BA, Liu KD (2021) Recovery of kidney function after dialysis initiation in children and adults in the US: a retrospective study of United States Renal Data System data. PLOS Med 18(2):e1003546. https://doi.org/10.1371/journal.pmed.1003546

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kwong YD, Liu KD, Hsu RK, Johansen KL, McCulloch CE, Seth D et al (2021) Recovery of kidney function among patients with glomerular disease starting maintenance dialysis. Am J Kidney Dis 77(2):303–305. https://doi.org/10.1053/j.ajkd.2020.06.012

    Article  PubMed  Google Scholar 

  27. Ku E, Hsu RK, McCulloch CE, Lo L, Copeland T, Siyahian S, Grimes B, Johansen KL (2022) Incidence and risk factors for dialysis reinitiation among patients with a history of dialysis dependency. Clin J Am Soc Nephrol 17(9):1346–1352. https://doi.org/10.2215/CJN.01870222

    Article  PubMed  Google Scholar 

Download references

Funding

This work was performed with local resources from the Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Author information

Authors and Affiliations

  1. Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Sofia E. Márquez-Macedo, Abril A. Perez-Arias, Óscar R. Pena-Vizcarra, María Fernanda Zavala-Miranda, Bernardo Juárez-Cuevas, Megan A. Navarro-Gerrard, Luis E. Morales-Buenrostro & Juan M. Mejía-Vilet

Authors
  1. Sofia E. Márquez-Macedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abril A. Perez-Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Óscar R. Pena-Vizcarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María Fernanda Zavala-Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernardo Juárez-Cuevas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Megan A. Navarro-Gerrard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis E. Morales-Buenrostro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juan M. Mejía-Vilet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan M. Mejía-Vilet.

Ethics declarations

Disclosures

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 373 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Márquez-Macedo, S.E., Perez-Arias, A.A., Pena-Vizcarra, Ó.R. et al. Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support. Clin Rheumatol 42, 2115–2123 (2023). https://doi.org/10.1007/s10067-023-06629-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06629-1

Keywords

Search

Navigation